new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)


Glaxosmithkline Biologicals Sa patents

Recent patent applications related to Glaxosmithkline Biologicals Sa. Glaxosmithkline Biologicals Sa is listed as an Agent/Assignee. Note: Glaxosmithkline Biologicals Sa may have other listings under different names/spellings. We're not affiliated with Glaxosmithkline Biologicals Sa, we're just tracking patents.

ARCHIVE: New 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "G" | Glaxosmithkline Biologicals Sa-related inventors

Date Glaxosmithkline Biologicals Sa patents (updated weekly) - BOOKMARK this page
05/25/17 new patent  Mutant staphylococcal antigens
05/25/17 new patent  Immunogenic combinations
05/18/17Novel methods for inducing an immune response
05/18/17Expression system
05/04/17Adjuvanting meningococcal factor h binding protein
04/20/17Uses of parasite macrophage migration inhibitory factors
04/13/17Combination vaccines with serogroup b meningococcus and d/t/p
03/23/17Heterologous expression of neisserial proteins
03/23/17Heterologous expression of neisserial proteins
03/23/17Oil/surfactant mixtures for self-emulsification
03/16/17Purification of secreted polysaccharides from s. agalactiae
03/16/17Immunogenic liposomal formulation
03/16/17Liposomal compositions for mucosal delivery
02/16/17Capsular polysaccharide solubilisation and combination vaccines
02/16/17Chimpanzee adenoviral vector-based filovirus vaccines
02/09/17Modified host cells and uses thereof
01/12/17Uspa2 protein constructs and uses thereof
01/12/17Modified meningococcal fhbp polypeptides
12/29/16Homogenous suspension of immunopotentiating compounds and uses thereof
12/29/16Purification of staphylococcus aureus type 5 and type 8 capsular saccharides
12/29/16Process for identifying culture conditions for a cell or organism
12/15/16Immunogenic proteins and compositions
12/08/16Injectable vaccines against multiple meningococcal serogroups
10/27/16Adjuvant compositions
10/20/16Integration of meningococcal conjugate vaccination
10/13/16Methods for making saccharide-protein glycoconjugates
09/15/16Salmonella conjugate vaccines
09/15/16Adjuvanted formulations of booster vaccines
09/08/16Influenza vaccine
08/25/16Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
08/11/16Meningococcal vaccine formulations
07/28/16Adsorption of immunopotentiators to insoluble metal salts
07/14/16Developments in meningococcal outer membrane vesicles
06/23/16Combination neisserial compositions
06/16/16Staphylococcus aureus proteins and nucleic acids
06/16/16Cycloalkyne derivatized saccharides
06/09/16Compositions for immunising against staphylococcus aureus
06/09/16Chlamydia antigens
06/02/16Combination neisserial compositions
05/19/16Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
05/05/16Inactivated dengue virus vaccine with aluminium-free adjuvant
04/21/16Immunogenic bacterial vesicles with outer membrane proteins
03/24/16Outer membrane vesicle (omv) vaccine comprising n. meningitidis serogroup b outer membrane proteins
03/10/16Mutant bacteria for production of generalized modules for mrmbrane antigens
02/25/16Neisserial antigenic peptides
02/11/16Multiple variants of meningococcal protein nmb1870
02/04/16Neisseria meningitidis antigens and compositions
02/04/16Outer membrane vesicle (omv) vaccine comprising n. meningitidis serogroup b outer membrane proteins
01/28/16Rna purification methods
01/28/16Haemophilus influenzae type b
01/07/16Improved poxviral vaccines
11/12/15Conjugates for protecting against diphtheria and/or tetanus
11/12/15Pseudomonas antigens and antigen combinations
11/05/15Purification of staphylococcus aureus type 8 capsular saccharides
10/01/15Non-cross-linked acellular pertussis antigens for use in combination vaccines
10/01/15Methods of inducing an immune response with compositions comprising a neisseria meningitidis 741 protein
09/17/15Bacterial outer membrane vesicles
04/23/15Method of vaccination against human papillomavirus
02/26/15Influenza vaccines
10/02/14Compositions and uses
08/21/14Liposome production using isopropanol
08/21/14Prame purification
07/10/14Immunogenic composition
02/27/14Fusion proteins and combination vaccines comprising haemophilus influenzae protein e and pilin a
Patent Packs
02/20/14Novel preventing or treating m tuberculosis infection
01/30/14Process for producing an immunogenic composition containing tetanus toxoid
09/27/12Tumor specific animal proteins
11/17/11Lipidated imidazoquinoline derivatives
11/18/10Tumour-specific animal proteins
11/18/10Method for refolding neisserial nspa protein
02/04/10Fusion protein
08/13/09Casb618 polynucleotides and polypeptides and their use

ARCHIVE: New 2017 2016 2015 2014 2013 2012 2011 2010 2009


This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. is not affiliated or associated with Glaxosmithkline Biologicals Sa in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Glaxosmithkline Biologicals Sa with additional patents listed. Browse our Agent directory for other possible listings. Page by